Engro Holdings H1 2026: Better Core Earnings Behind a 41% Reported Profit Drop
Engro Holdings’ core earnings improved as Deodar and portfolio businesses strengthened, but reported profit, cash conversion and Q2 momentum weakened.
In-depth company stories built from financial results, announcements, and sector developments to help investors understand business momentum, strategic direction, and future outlook.
Engro Holdings’ core earnings improved as Deodar and portfolio businesses strengthened, but reported profit, cash conversion and Q2 momentum weakened.
EFU Life’s H1 premium growth was strong, but mix, market-driven gains, tax relief and a 43% rights issue complicate the earnings picture.
DLL’s H1 profit masks a Q1 portfolio loss, Q2 recovery and tax reversal. Cash conversion and the post-merger balance sheet matter next.
DGKC’s FY2026 profit and cash flow improved, but a softer derived Q4 margin and debt-funded Rafhan investment reshape the next-cycle test.
Crescent Star Insurance wrote more premium in H1 2026, but weak earned-premium conversion, high costs and investment losses drove a sharp reversal.
Bata Pakistan’s Q2 margin recovered sharply, but rising overheads, leases and weak cash conversion kept H1 2026 in loss.
Avanceon’s first-half revenue expanded strongly, but lower group margins, rising operating costs and weaker other income produced a loss. Cash flow improved through collections and customer advances, making execution quality the key next-cycle test.
Attock Refinery’s core margin recovered sharply in FY2026, but associate income, inventory growth and supplier financing complicate the headline profit surge.
Atlas Insurance grew premium and underwriting profit in H1 2026, but realized equity gains supplied most of the earnings acceleration as claims and cash conversion remained key watchpoints.
Atlas Battery’s FY2026 revenue held broadly flat, but weaker pricing and mix economics, a working-capital reversal and heavy tax charges produced a full-year loss.
Attock Petroleum’s FY2026 profit surged as gross margin recovered, but an implied Q4 slowdown reveals the limits of inventory-led earnings.
Adamjee Life’s H1 2026 profit fell as investment gains and cost absorption weakened, while rising claims created a sharper cash-flow strain.